ResMed Inc. (RMD): Smart Entry Points Emerge After Sharp Pullback

What's Happening Right Now

ResMed took a hard hit last week. The stock closed at $246.88 on October 31st--down nearly 6% in two days and 18% from its August highs. Volume exploded to 2.5 million shares on the 31st (more than double its average), showing panic selling. But here's the twist: Wall Street analysts aren't panicking. They're raising price targets while others flee. Let's unpack why.

News Sentiment: Bullish Wall Street vs. Bearish Market

The disconnect is glaring.

• Three major upgrades hit in the last 10 days: RBC ($303 target), Keybanc ($299), and Morgan Stanley ($304).
• Mizuho trimmed its target slightly to $300 but kept its "Outperform" rating.
• Why the gap? Analysts see long-term strength in ResMed’s cloud-based sleep apnea solutions (like AirView and myAir) and recent acquisitions in home healthcare software. The market, however, is reacting to October’s broader healthcare selloff and ResMed’s high debt load.
• Translation: Institutions may be using this dip to build positions ahead of Q4 earnings.

Price Action: Critical Support Level in Play

October’s collapse wasn’t random--it broke key technical levels.

• The plunge: Stock fell from $277 on October 1st to $239.41 (intraday low on Oct 31)--its weakest point since March.
• Where it’s holding: October 31st’s close ($246.88) stopped just $0.50 above the technical support zone at $246.40 (per Bollinger Band analysis).
• Volume tells the story:
• October 24th: 1.1M shares traded as price dropped 2.3% (selling pressure)
• October 31st: 2.5M shares traded as price rebounded off lows (buyers stepping in)
• The setup: If $246.40 holds, we could see a sharp bounce toward $260. If it breaks, next support is at $230.

Predictive Outlook: Short-Term Bounce Likely

Don’t overhype the AI predictions--but they align with technicals.

• AI model signals:
• Day 1: +1.85% move (likely already priced in)
• Day 3: +4.54% potential jump (watch November 4th)
• Why this makes sense:
• MACD just flipped bullish (crossing above signal line)
• Relative Strength Index (RSI) is oversold at 28--historically precedes rebounds
• Analysts’ average target ($293.47) implies 18.9% upside from here
• Reality check: The +4.54% prediction is not guaranteed--it’s based on recent volatility patterns. But with 15 "Buy" ratings backing it, the odds favor a rebound.

Your Action Plan: Tactical Entry Strategy

This isn’t a blind gamble--it’s a calculated play with clear triggers.

✅ Do This Now:

• Buy in small increments between $246.90 and $248.90 (aligns with technical support and recommendation data)
• Set stop-loss at $222.20 (below major support--limits downside